[go: up one dir, main page]

AR053109A1 - DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2. - Google Patents

DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.

Info

Publication number
AR053109A1
AR053109A1 ARP050105527A ARP050105527A AR053109A1 AR 053109 A1 AR053109 A1 AR 053109A1 AR P050105527 A ARP050105527 A AR P050105527A AR P050105527 A ARP050105527 A AR P050105527A AR 053109 A1 AR053109 A1 AR 053109A1
Authority
AR
Argentina
Prior art keywords
ring
alkyl
heterocyclyl
atoms
group
Prior art date
Application number
ARP050105527A
Other languages
English (en)
Inventor
Justin F Bowers
Jeffrey P Poyser
Paul Turner
David Waterson
Jon Winter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36084353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053109(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0428327A external-priority patent/GB0428327D0/en
Priority claimed from GB0520325A external-priority patent/GB0520325D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR053109A1 publication Critical patent/AR053109A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un método de preparacion, composiciones farmacéuticas y usos en medicamentos de utilidad en el tratamiento de afecciones mediadas por quimioquinas C-C. Reivindicacion 1: Un compuesto de la formula (1) Q-L-W-C(=X)-Z-P caracterizado porque Q es una amina de la formula -N(R1)(R2) donde R1 y R2 se seleccionan independientemente entre H (con la condicion que R1 y R2 no sean ambos H), C1-6 alquilo, C3-7 cicloalquilo, C2-6 alquenilo, C2-6 alquinilo, cicloalquil-alquilo de hasta 14 átomos de anillos y cadenas, heterociclilo de hasta 7 átomos de anillos, heterociclilalquilo de hasta 14 átomos de anillos y cadenas, heterociclil-cicloalquilo de hasta 14 átomos de anillos, heterociclil-heterociclialquilo de hasta 20 átomos de anillos y cadenas, heterociclil-arlalquilo de hasta 20 átomos de anillos y cadenas, heterociclil-arilo de hasta 20 átomos de anillo; aril-alquilo de hasta 14 átomos de anillos y cadenas, aril-heterociclil-alquilo de hasta 20 átomos de anillos y cadenas, aril-oxi- alquilo de hasta 14 átomos de anillos y cadenas, aril-cicloalquilo de hasta 14 átomos de anillos, aril-arilalquilo de hasta 20 átomos de anillos y cadenas, donde cada cadena o anillo está, independientemente entre sí, sustituido opcionalmente con hasta 3 sustituyentes cada uno seleccionado independientemente entre halogeno, hidroxi, C1-6 alquilo, C1-4 alcoxi sustituido opcionalmente con C1-4 alcoxi, ciano, C1-4 alquilsulfonilo, trifluorometilo, carboxi, C1-4 alcoxicarbonilo, C1-2 alquiloxicarbonilfenilo, fenilo, NH2, NO2, =O, C1-4 alquilcarbonilo, C3-7 cicloalquil-heteroarilo de hasta 10 átomos de anillos y un átomo de N de un anillo heteroaromático puede estar sustituido con un grupo oxido, o R1 y R2 tomados juntos co el átomo de N de Q representan un anillo saturado de 4-7 miembros que comprende otro heteroátomo opcional seleccionado entre O, N o S y opcionalmente sustituido con hasta 3 sustituyentes cada uno de los cuales se selecciona independientemente entre los sustituyentes enumerados precedentemente; L es un ligador que comprende C1-6 alquilo, C1-6 alquilo-C4-10 cicloalquilo o C4-10 cicloalquil-C1-6-alquilo donde en cada caso el grupo alquilo y/o cicloalquilo puede comprender además 1, 2 o 3 heteroátomos seleccionados independientemente entre N, O S y/o un grupo =O; o tomados juntos con el átomo de N de la amina Q y R2, L representa un grupo heterociclilo o heterociclil-C1-6 alquilo, donde el grupo heterociclilo es de hasta 10 átomos de anillos y donde, además del átomo de N de la amina Q el grupo heterociclilo y/o alquilo puede comprender opcionalmente 1 o 2 heteroátomos adicionales seleccionados independientemente entre N, O S y/o un grupo =O; y donde cada cadena o anillo está independientemente entre sí, sustituido opcionalmente con hidroxi, halogeno o C1-4 alquilo; con la condicion que (i) cuando L es un grupo C5-7 cicloalquil-C1-6 alquilo definido precedentemente, entonces Q no es un anillo heterocíclico saturado que tiene dos heteroátomos de N y está sustituido o no sustituido sobre un heteroátomo de N del anillo con un grupo protector, y (ii) cuando L representa un grupo heterociclil C1-6 alquilo, definido precedentemente, y el grupo heterociclilo no comprende heteroátomos adicionales, entonces R1 no representa un heteroanillo saturado que tiene un solo heteroátomo de N y dicho anillo no está sustituido o posee un grupo protector sobre el heteroátomo de N; W es un anillo alifático de6 o 7 miembros que comprende los átomos de anillos Y1 y Y2 está ligado por Y1 e Y2 a los grupos L y C(=X), respectivamente, Y1 y Y2 se seleccionan independientemente entre N y C, y cuando Y1 e Y2 son ambos N o ambos C entonces W está sustituido opcionalmente en cualquier átomo del anillo con 1, 2 o 3 grupos R1 seleccionados independientemente entre sí o con un puente C2 entre dos átomos de C del anillo; y cuando Y1 es C e Y2 es N entonces Y1 está sustituido opcionalmente con hidroxi o halogeno, X es O, N, N-CN o S; Z es NR3, donde R3 es H o alquilo C1-4, o cuando Y2 es N entonces Z también puede ser O; P es un grupo arilo o heteroarilo C5-10 monocíclico o bicíclico de hasta 20 átomos de anillos, cada uno de los cuales está sustituido opcionalmente con 1, 2 o 3 sustituyentes seleccionados independientemente entre halogeno, C1-4alquilo, C2-4 alquenilo, C2-4 alquinilo, cano, trifluorometilo, trifluorometoxi, C1-4alcoxi, C1-4 alquiltio, trifluorometiltio, carboxi C1-4-alquilo y NO2; o P está sustituido opcionalmente con fenilo, fenoxi o aralquiloxi de hasta 10 átomos de C cada uno sustituido opcionalmente con 1 o 2 de cualquier otro sustituyente enumerado precedentemente para P; o una sal o solvato aceptable para uso farmacéutico del mismo. Reivindicacion 18:Un proceso para preparar un compuesto de acuerdo con la cláusula 1, o una sal o solvato aceptable para uso farmacéutico del mismo, caracterizado porque dicho proceso comprende: (i) hacer reaccionar un compuesto de la formula (2) (X)C-Z-P con un compuesto de la formula (3) Q-L-W o (ii) hacer reaccionar un compuesto de la formula (4) Q-L-W-C(X)-Z-P con un compuesto de la formula (5) Q donde Q, P, Z, -C(X), W y L(n) son como se definieron con relacion a la formula (1), excepto Q que es como se definio para la formula (4) donde comprende un grupo amino libre para su reaccion con Q' como una arte sustituyente de Q; y después, opcionalmente, comprende uno o más de los pasos (i), (ii) o (iii) en cualquier orden: (i) eliminar todos los grupos protectores; (ii) convertir el compuesto de la formula (1) en otro compuesto de la formula (1); (iii) formar una sal.
ARP050105527A 2004-12-24 2005-12-26 DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2. AR053109A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0428327A GB0428327D0 (en) 2004-12-24 2004-12-24 Method
GB0520325A GB0520325D0 (en) 2005-10-06 2005-10-06 Method

Publications (1)

Publication Number Publication Date
AR053109A1 true AR053109A1 (es) 2007-04-25

Family

ID=36084353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105527A AR053109A1 (es) 2004-12-24 2005-12-26 DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.

Country Status (17)

Country Link
US (4) US7906645B2 (es)
EP (1) EP1831164A1 (es)
JP (2) JP5118975B2 (es)
KR (1) KR20070091677A (es)
AR (1) AR053109A1 (es)
AU (2) AU2005317928B2 (es)
BR (1) BRPI0519288A2 (es)
CA (1) CA2589748C (es)
IL (1) IL183665A (es)
MX (1) MX2007007428A (es)
MY (1) MY147400A (es)
NO (1) NO20073729L (es)
NZ (1) NZ555770A (es)
RU (1) RU2423349C2 (es)
TW (1) TW200633979A (es)
UY (1) UY29312A1 (es)
WO (1) WO2006067401A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
EP1798227A4 (en) * 2004-09-09 2009-09-09 Res Found Itsuu Lab SEROTONIN 5-HT3 RECEPTOR AGONIST
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
EP1831164A1 (en) * 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
AU2006292598B2 (en) 2005-09-16 2012-06-21 Janssen Pharmaceutica N.V. Cyclopropyl amines as modulators of the histamine H3 receptor
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
US20070155727A1 (en) * 2005-12-29 2007-07-05 Schering Aktiengessellschaft Amide inhibitors of leukotriene A4 hydrolase
FR2895989B1 (fr) * 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
HUE032761T2 (en) 2006-12-14 2017-10-30 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanylbenzamide derivatives
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
ES2439969T3 (es) * 2008-07-16 2014-01-27 F. Hoffmann-La Roche Ag Nuevos compuestos heterocíclicos para el tratamiento de enfermedades cardiovasculares
US20100152197A1 (en) * 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
SMT201700035T1 (it) 2011-05-13 2017-03-08 Array Biopharma Inc Composti di pirrolidinil urea, pirrolidinil tiourea e pirrolidinil guanidina come inibitori di chinasi trka
WO2021108408A1 (en) 2019-11-25 2021-06-03 Amgen Inc. Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3541085A (en) * 1969-05-09 1970-11-17 American Cyanamid Co Method of preparing thiotricyclic compounds
JPS5331669A (en) 1976-09-06 1978-03-25 Kissei Pharmaceut Co Ltd Novel n-acylpiperidinecaroxyanilide derivatives and their preparation
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
DE3636278A1 (de) 1986-10-24 1988-05-05 Hoechst Ag Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung
IL95994A0 (en) * 1989-11-15 1991-07-18 American Home Prod Carbamate esters and pharmaceutical compositions containing them
JP2864489B2 (ja) * 1991-02-27 1999-03-03 吉富製薬株式会社 喘息治療剤
EP0589985A1 (en) * 1991-06-21 1994-04-06 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
CA2077252C (en) 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR19990067047A (ko) 1995-10-25 1999-08-16 이.아이,듀우판드네모아앤드캄파니 제초성 술폰아미드
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
AU9206798A (en) * 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
WO2000035877A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
US6506751B1 (en) * 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US6964974B2 (en) * 2000-09-08 2005-11-15 Hoffmann-La Roche Inc. 2,3-oxidosqualene-lanosterol cyclase inhibitors
JP2004517062A (ja) 2000-11-13 2004-06-10 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｋ−３およびｎｋ−２アンタゴニストとしてのキノリン誘導体
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002079151A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham P.L.C. 3-substituted indoels or fused pyrroles as antagonists of the chemokine mcp-1 (ccr2b) receptor
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
EP1522314B1 (en) * 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
AU2003284975B2 (en) * 2002-10-30 2009-04-02 Merck Sharp & Dohme Corp. Heteroarylpiperidine modulators of chemokine receptor activity
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US20040147502A1 (en) * 2002-12-17 2004-07-29 Bisacchi Gregory S. Beta lactam compounds and their use as inhibitors of tryptase
GB0308801D0 (en) 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
KR100799534B1 (ko) * 2004-02-27 2008-01-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(1)
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
JP4763697B2 (ja) * 2004-08-09 2011-08-31 メディジーン リミテッド Ｃｄ８０抑制剤としての免疫調整性オキソピラゾロシンノリン類
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
EP1831164A1 (en) * 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives

Also Published As

Publication number Publication date
TW200633979A (en) 2006-10-01
NZ555770A (en) 2010-12-24
US20090099156A1 (en) 2009-04-16
EP1831164A1 (en) 2007-09-12
AU2010212346B2 (en) 2012-11-22
JP5118975B2 (ja) 2013-01-16
NO20073729L (no) 2007-08-08
JP2012214507A (ja) 2012-11-08
US20140038978A1 (en) 2014-02-06
AU2010212346A1 (en) 2010-09-09
RU2423349C2 (ru) 2011-07-10
US8710224B2 (en) 2014-04-29
US20120264762A1 (en) 2012-10-18
UY29312A1 (es) 2006-07-31
MY147400A (en) 2012-11-30
BRPI0519288A2 (pt) 2009-01-06
WO2006067401A1 (en) 2006-06-29
JP2008525397A (ja) 2008-07-17
CA2589748A1 (en) 2006-06-29
AU2005317928B2 (en) 2010-06-10
US20110136820A1 (en) 2011-06-09
KR20070091677A (ko) 2007-09-11
MX2007007428A (es) 2007-07-16
HK1110868A1 (en) 2008-07-25
IL183665A0 (en) 2007-09-20
AU2005317928A1 (en) 2006-06-29
IL183665A (en) 2012-02-29
RU2007130144A (ru) 2009-02-20
US7906645B2 (en) 2011-03-15
CA2589748C (en) 2013-08-13

Similar Documents

Publication Publication Date Title
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
AR054799A1 (es) Derivados de oxindol
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
AR051093A1 (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
PE20010482A1 (es) Derivados de 3-ureido-pirazol y procedimiento para su preparacion
AR078786A1 (es) Derivados de la cromenona
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
GT200000167A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas.
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR051094A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR055144A1 (es) Inhibidor de secrecion acida
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR039399A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal